Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 916.90 |
| Open | 913.50 |
| Bid | 927.40 x 0 |
| Ask | 927.30 x 0 |
| Day's range | 908.80 - 931.60 |
| 52-week range | 504.40 - 942.60 |
| Volume | |
| Avg. volume | 2,697,505 |
| Market cap | 4.131T |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 46.50 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 12.80 (1.38%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | N/A |
- Investor's Business Daily
Netflix Stock Faces Test Of Time As IBD 50 Oil Stock Nears 10-Bagger Status
As a stock's advance gets long in the tooth, shares may still form bases, but late-stage formations carry risks. Netflix stock and Novo Nordisk, two IBD 50 growth stocks, are in late-stage bases. The fourth or fifth bases in a long-term advance are more prone to failure than earlier patterns, mainly because it gets harder to extend gains the longer that shares keep rising.
- Investor's Business Daily
Ozempic Maker Novo Nordisk Stock Up More Than 31% In 2024, But Is It Too Late To Buy Shares?
Novo Nordisk stock traded close to a buy point Friday afternoon as shares bounced from their 21-day line this week.
- Bloomberg
Goldman Sees Obesity-Drug Market Growing to $130 Billion by 2030
(Bloomberg) -- Goldman Sachs Group Inc. sees growing potential for the global market for weight-loss drugs by the end of the decade.Most Read from BloombergWall Street Billionaires Are Rushing to Back Trump, Verdict Be DamnedDonald Trump Becomes First Former US President Guilty of CrimesTrump Is Guilty on All Counts in Hush-Money Case. Now What?South Africa Election Results With 29% Voting Districts InFed’s Favored Inflation Gauge Cools, Spending Unexpectedly DropsThe obesity market — currently
